An expert discussed fam-trastuzumab deruxtecan-nxki for HER2-mutant and -overexpressing non-small cell lung cancer.

Fact checked by Marley Hall Medically reviewed by Marla Anderson, MD The Food and Drug Administration (FDA) granted priority review for Enhertu (fam-trastuzumab deruxtecan-nxki) in 2024. This drug ...

The antibody–drug conjugate ifinatamab deruxtecan (I-DXd ... luxury and a cough marks the sound of an inner battle. Interstitial lung disease (ILD), a condition characterized by inflammation ...

MSD and Daiichi Sankyo have revealed some of the clinical data that prompted them to start pivotal testing of ifinatamab deruxtecan (I-DXd) in patients with previously treated, extensive-stage ...

Additionally, the study did not establish the efficacy of T-Duo in patients previously treated with trastuzumab deruxtecan. This study was supported by Byondis B.V. Co-authors Evelyn van den Tweel ...

Patritumab deruxtecan’s safety profile in the trial was in line with previous lung cancer studies, without any new safety ...